PCF received a donation of $5.4 million from the Movember Foundation to help fund the 2017 Challenge Awards. Of these funds, more than $4.7 million came from the 2016 Movember U.S. Campaign. $687,000 came from the 2016 Distinguished Gentleman’s Ride, a vintage motorcycle ride which happens globally in September, to raise funds for men's health.
Find out more about the Distinguished Gentleman's Ride and register for 2017, here.
Since 2007, the Movember Foundation has contributed more than $50 million to PCF to further new discoveries in prostate cancer research.
As part of PCF’s commitment to accelerate research and innovation in prostate cancer, Challenge Award teams are required to include at least three investigators, one of whom must be a young investigator. Each proposal submitted to PCF was subjected to a rigorous peer review process that assessed the scientific merit of the project as well as its potential impact for patients.
“The generous donation from the Movember Foundation enables teams of research scientists to accelerate the delivery of life-extending and life-saving therapies for men living with prostate cancer,” said Jonathan W. Simons, MD, president and chief executive officer, PCF.
“As we embark upon the 10th year of our remarkable relationship with the Movember Foundation, we are grateful to continue our partnership as we continue to help further advance therapies and defeat prostate cancer once and for all.”
Paul Villanti, Director of Programmes, the Movember Foundation, said;
“We’re delighted that the Mo Bros and Mo Sistas have this year been joined by the Distinguished Gentleman’s Ride in driving the progress so sorely needed for men in the US, and around the world.”“Work of this quality is only made possible through the incredible efforts of our fundraising community.”
The following projects were selected to receive a 2017 Movember Foundation-PCF Challenge Award. If you would like to read about each in depth, click here:
Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer ($1 Million), led by Felix Feng, MD (University of California, San Francisco); researchers aim to identify mechanisms by which prostate cancers gain resistance to PARP-inhibitors and investigate therapeutic approaches for treating these patients.
Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate ($1 Million), led by Joshua Lang, MD (University of Wisconsin); a clinical trial testing a therapy targeting TROP-2, a protein highly expressed on prostate cancer cells will be conducted.
Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence ($1 Million), led by Howard Scher, MD (Memorial Sloan Kettering Cancer Center); researchers will develop a precision medicine approach for treating prostate cancer patients with high-risk localized disease or low-volume metastatic tumors with a potentially curative regimen that includes an intense combination of androgen-targeted therapies, followed by maximal treatment of the primary tumor.
Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets ($1 Million), led by Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center); researchers are working to develop biomarkers that can be used to identify patients diagnosed with metastatic prostate cancer who will benefit from treatment of the primary prostate tumor.
Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer ($1 Million), led by Nupam Mahajan, PhD (H. Lee Moffitt Cancer Center); preclinical studies to develop and optimize novel inhibitors of ACK1, a molecular pathway that regulates the androgen receptor, as a strategy to overcome resistance to androgen-targeted therapies will be performed.
The following project was selected to receive a 2017 Movember Foundation-Distinguished Gentleman’s Ride Challenge Award:
Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer ($1 Million), led by Douglas McNeel, MD, PhD (University of Wisconsin); a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1 will be conducted.
The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, it advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer.
The Movember Foundation has been working together with PCF in proud partnership for 10 years. To find out about the impact the Movember Foundation's investments have made in prostate cancer research, click here.
.com_Carousel.jpg)
.png)
